Twelve-month Study on the Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia

Trial Profile

Twelve-month Study on the Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 30 Mar 2016

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Neutropenia
  • Focus Therapeutic Use
  • Sponsors Sandoz
  • Most Recent Events

    • 04 Nov 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 27 Jul 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 May 2015 to 1 Dec 2015.
    • 27 Jul 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 May 2015 to 1 Dec 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top